Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer

Gynecologic Oncology

Volumn 129, Issue 3, 2013, Pages 452-458

  Armstrong, Deborah K ^a   White, Allen J ^b   Weil, Susan C ^c   Phillips, Martin ^c   Coleman, Robert L ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b TEXAS ONCOLOGY   (United States)

^c Morphotek Inc   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Carboplatin; Farletuzumab; Ovarian cancer; Platinum sensitive; Taxane

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; FARLETUZUMAB; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG FATALITY; FALLOPIAN TUBE CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; IMMUNOGENICITY; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG HYPERSENSITIVITY; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; TAXOIDS;

EID: 84877579319     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.03.002     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
2. L. Huang, K.A. Cronin, K.A. Johnson, A.B. Mariotto, and E.J. Feuer Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 112 10 2008 2289 2300
3. S. Miotti, M. Bagnoli, F. Ottone, M.I. Colnaghi, and S. Canevari Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines J Cell Biochem 65 4 1997 479 491
4. M. Bagnoli, S. Canevari, M. Figini, D. Mezzanzanica, F. Raspagliesi, and A. Tommassetti A step further in understanding the biology of the folate receptor in ovarian carcinoma Gynecol Oncol 88 1 2003 S140 S144
5. F. Bottero, A. Tomassetti, S. Canevari, S. Miotti, S. Ménard, and M.I. Colnaghi Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo Cancer Res 53 1993 5791 5796
6. G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli, and M. Boiocchi Overexpression of folate binding protein in ovarian cancers Int J Cancer (Pred Oncol) 74 1997 193 198
7. W. Ebel, E.L. Routhier, B. Foley, S. Jacob, J.M. McDonough, and R.K. Patel Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha Cancer Immun 7 2007 6 13
8. B.A. Kamen, and A.K. Smith Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro Cancer Chemother Pharmacol 70 2012 113 120
9. W.A. Spannuth, Y.G. Lyn, W.M. Merritt, A.M. Nick, S.M. Mangala, and G.N. Armaiz-Pena Therapeutic efficacy of folate receptor α blockade with MORAb-003 in ovarian cancer Gynecol Oncol 108 2008 S135 [abstract 307]
10. W.A. Spannuth, A.K. Sood, and R.L. Coleman Farletuzumab in epithelial ovarian cancer Expert Opin Biol Ther 10 3 2010 431 437
11. J.A. Konner, K.M. Bell-McGuinn, P. Sabbatini, M.L. Hensley, W.P. Tew, and N. Pandit-Tasker Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study Clin Cancer Res 16 21 2010 5288 5295
12. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines) J Natl Cancer Inst 92 3 2000 205 216
13. P.M. Smith-Jones, N. Pandit-Taskar, W. Cao, J. O'Donoghue, M.D. Phillips, and J. Carrasquillo Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003 Nucl Med Biol 35 2008 343 351
14. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 2003 187s 193s
15. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
16. G.J.S. Rustin, M. Quinn, T. Thigpen, A. Du Bois, E. Pujade-Lauraine, and A. Jakobsen Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) [correspondence] J Natl Cancer Inst 96 6 2004 487 488
17. A.E. Guppy, and G.J.S. Rustin CA125 response; can it replace traditional response criteria in ovarian cancer? Oncologist 7 2002 437 443
18. K.N. Moore, C. Tian, D.S. McMeekin, J.T. Thigpen, M.E. Randall, and H.H. Gallion Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis Cancer 116 2010 5407 5414
19. M. Markman, J. Markman, K. Webster, K. Zanotti, B. Kulp, and G. Peterson Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design J Clin Oncol 22 15 2005 3120 3125
20. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, and P. Vasey Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 20 2010 3323 3329
21. C.K. Lee, R.J. Simes, C. Brown, S. Lord, U. Wanger, and M. Plante Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer Br J Cancer 105 2011 1144 1150
22. C. Clopper, and S. Pearson The use of confidence or fiducial limits illustrated in the case of the Binomial Biometrika 26 4 1934 404 413
23. E.L. Kaplan, and P. Meier Nonparametric estimations from incomplete observations J Am Stat Assoc 53 282 1958 457 481
24. R. Brookmeyer, and J. Crowley A confidence interval for the median survival time Biometrics 38 1 1982 29 41
25. M.K. Parmar, J.A. Ledermann, N. Colombo, A. Du Bois, J.-F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 2003 2099 2106
26. J. Pfisterer, M. Plante, I. Vergote, A. DuBois, H. Hirte, and A.J. Lacave Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 29 2006 4699 4707
27. G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, and M. Melpignano Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer Gynecol Oncol 81 1 2001 3 9
28. A.J. Gonzalez-Martin, E. Calvo, I. Bover, M.J. Rubio, A. Arcusa, and A. Cadaso Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study Ann Oncol 16 5 2005 749 755
29. M.L. Harrison, M.E. Gore, D. Spriggs, S. Kaye, A. Iasonos, and M. Hensley Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials Gynecol Oncol 106 3 2007 469 475
30. K.M. Cook, and W.D. Figg Angiogenesis inhibitors: current strategies and future prospects CA Cancer J Clin 60 4 2010 222 243